Spero Therapeutics up after Evercore raises rating to 'outperform'

Spero Therapeutics

23/09/2022 15:19

** Spero Therapeutics Inc's shares  SPRO.O  rise 5% to $2.3
    ** Evercore ISI raises rating to "outperform" from "in
line"; PT to $8 from $2
    ** Brokerage says GSK deal makes a lot of sense given SPRO's
 limited access to capital
    ** We see the deal itself not only as positive for future
cash flow, but it also affords flexibility to advance their
pipeline - Evercore
    ** SPRO said on Monday British drugmaker GSK Plc  GSK.L  to
take a stake in SPRO as part of licensing agreement for its
experimental antibiotic for complicated urinary tract infections
 urn:newsml:reuters.com:*:nL4N30T2MV
    ** Including session gains, stock down ~86% YTD
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))